Serum Ferritin as a Prognostic Biomarker for Survival in Relapsed or Refractory Metastatic Colorectal Cancer

Serum Ferritin as a Prognostic Biomarker for Survival in Relapsed or Refractory Metastatic Colorectal Cancer

This study investigated the prognostic impact of serum ferritin for survival in patients with relapsed or refractory metastatic colorectal cancer (mCRC). This retrospective cohort study reviewed clinicopathological characteristics and laboratory biomarkers in 120 mCRC patients being treated with Kor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Cancer 2016-01, Vol.7 (8), p.957-964
Hauptverfasser: Lee, Sookyung, Song, Anna, Eo, Wankyu
Format: Artikel
Sprache:eng
Schlagworte:
Research Paper
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 964
container_issue 8
container_start_page 957
container_title Journal of Cancer
container_volume 7
creator Lee, Sookyung
Song, Anna
Eo, Wankyu
description This study investigated the prognostic impact of serum ferritin for survival in patients with relapsed or refractory metastatic colorectal cancer (mCRC). This retrospective cohort study reviewed clinicopathological characteristics and laboratory biomarkers in 120 mCRC patients being treated with Korean Medicine (KM). The overall survival (OS) of patients was calculated using the Kaplan-Meier method, and statistical significance was assessed using the log-rank test. Univariate and multivariate analyses of Cox proportional hazards regression were used to evaluate the prognostic impact for survival in relapsed or refractory mCRC patients. Of the patients, 62.5% had liver metastases, 74.1% underwent greater than second-line chemotherapy, and 80.8% underwent surgery. Median OS was 7.6 months for all patients after the initiation of KM treatment, which was begun 13.7 months, on average, after mCRC diagnosis. Concerning prognostic factors such as the presence of liver metastasis (p = 0.024), high carcinoembryonic antigen level (CEA > 5 ng/mL, p = 0.044), elevated C-reactive protein (CRP ≥ 10.0 mg/L, p = 0.000), high absolute monocyte count (AMC > 413.3 cells/μL, p = 0.034), elevated serum ferritin (ferritin ≥ 150 ng/mL, p = 0.002), low hemoglobin level (Hb < 12 g/dL, p = 0.026) and low albumin (albumin < 3.5 g/dL, p = 0.003) were associated with increased hazard ratios and poor survival. According to the multivariate proportional hazards model with backward and forward manners, albumin (albumin < 3.5 g/dL; hazard ratio (HR) 2.218, 95% confidence interval (CI) 1.135 - 3.990, p = 0.019), CRP (CRP ≥ 10.0 mg/L; HR 2.506, 95% CI 1.644 - 3.822, p = 0.000), CEA (CEA > 5 ng/mL; HR 2.040, 95% CI 1.203 - 3.460, p = 0.008), and serum ferritin (ferritin ≥ 150 ng/mL; HR 1.763, 95% CI 1.169 - 2.660, p = 0.007) were independent prognostic biomarkers of survival in mCRC patients. These results indicate that serum ferritin acts as an independent prognostic biomarker for survival in relapsed or refractory mCRC patients.
doi_str_mv 10.7150/jca.14797
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4910588</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1797870836</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-7a3ad7b0dc6c3902f8b57c071975f4e5aa6aa87918396969774704bb86c32cba3</originalsourceid><addsrcrecordid>eNpVkU1vFDEMhiMEolXpoX8A5QiHLckmM85ckGDVAlJRqxbOkSfrKSmzk8XJrNR_T_pBVZyDo_jJm9ivEEdaHYNu1IebgMfaQgcvxL52BhZd29qXz_Z74jDnG1XDdEuw5rXYW4LRBly7L8Yr4nkjT4k5ljhJzBLlBafrKeUSg_wc0wb5N7EcEsurmXdxh6Os5CWNuM20lvX8kgbGUBLfyu9UMBe8u7tKY2IKpfIrnALxG_FqwDHT4WM-ED9PT36svi7Ozr98W306WwRrdVkAGlxDr9ahDaZTy8H1DQQFuoNmsNQgtogOutph19YFYEHZvncVX4YezYH4-KC7nfsNrQNNhXH0W461l1ufMPr_K1P85a_TzttOq8a5KvDuUYDTn5ly8ZuYA40jTpTm7HUdtwPlTFvR9w9o4JQz0_D0jFb-ziBfDfL3BlX27fN_PZH_7DB_AaR-jXI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1797870836</pqid></control><display><type>article</type><title>Serum Ferritin as a Prognostic Biomarker for Survival in Relapsed or Refractory Metastatic Colorectal Cancer</title><source>PubMed Central</source><source>EZB Electronic Journals Library</source><source>PubMed Central Open Access</source><creator>Lee, Sookyung ; Song, Anna ; Eo, Wankyu</creator><creatorcontrib>Lee, Sookyung ; Song, Anna ; Eo, Wankyu</creatorcontrib><description>This study investigated the prognostic impact of serum ferritin for survival in patients with relapsed or refractory metastatic colorectal cancer (mCRC). This retrospective cohort study reviewed clinicopathological characteristics and laboratory biomarkers in 120 mCRC patients being treated with Korean Medicine (KM). The overall survival (OS) of patients was calculated using the Kaplan-Meier method, and statistical significance was assessed using the log-rank test. Univariate and multivariate analyses of Cox proportional hazards regression were used to evaluate the prognostic impact for survival in relapsed or refractory mCRC patients. Of the patients, 62.5% had liver metastases, 74.1% underwent greater than second-line chemotherapy, and 80.8% underwent surgery. Median OS was 7.6 months for all patients after the initiation of KM treatment, which was begun 13.7 months, on average, after mCRC diagnosis. Concerning prognostic factors such as the presence of liver metastasis (p = 0.024), high carcinoembryonic antigen level (CEA &gt; 5 ng/mL, p = 0.044), elevated C-reactive protein (CRP ≥ 10.0 mg/L, p = 0.000), high absolute monocyte count (AMC &gt; 413.3 cells/μL, p = 0.034), elevated serum ferritin (ferritin ≥ 150 ng/mL, p = 0.002), low hemoglobin level (Hb &lt; 12 g/dL, p = 0.026) and low albumin (albumin &lt; 3.5 g/dL, p = 0.003) were associated with increased hazard ratios and poor survival. According to the multivariate proportional hazards model with backward and forward manners, albumin (albumin &lt; 3.5 g/dL; hazard ratio (HR) 2.218, 95% confidence interval (CI) 1.135 - 3.990, p = 0.019), CRP (CRP ≥ 10.0 mg/L; HR 2.506, 95% CI 1.644 - 3.822, p = 0.000), CEA (CEA &gt; 5 ng/mL; HR 2.040, 95% CI 1.203 - 3.460, p = 0.008), and serum ferritin (ferritin ≥ 150 ng/mL; HR 1.763, 95% CI 1.169 - 2.660, p = 0.007) were independent prognostic biomarkers of survival in mCRC patients. These results indicate that serum ferritin acts as an independent prognostic biomarker for survival in relapsed or refractory mCRC patients.</description><identifier>ISSN: 1837-9664</identifier><identifier>EISSN: 1837-9664</identifier><identifier>DOI: 10.7150/jca.14797</identifier><identifier>PMID: 27313786</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher</publisher><subject>Research Paper</subject><ispartof>Journal of Cancer, 2016-01, Vol.7 (8), p.957-964</ispartof><rights>Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-7a3ad7b0dc6c3902f8b57c071975f4e5aa6aa87918396969774704bb86c32cba3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910588/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910588/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27313786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Sookyung</creatorcontrib><creatorcontrib>Song, Anna</creatorcontrib><creatorcontrib>Eo, Wankyu</creatorcontrib><title>Serum Ferritin as a Prognostic Biomarker for Survival in Relapsed or Refractory Metastatic Colorectal Cancer</title><title>Journal of Cancer</title><addtitle>J Cancer</addtitle><description>This study investigated the prognostic impact of serum ferritin for survival in patients with relapsed or refractory metastatic colorectal cancer (mCRC). This retrospective cohort study reviewed clinicopathological characteristics and laboratory biomarkers in 120 mCRC patients being treated with Korean Medicine (KM). The overall survival (OS) of patients was calculated using the Kaplan-Meier method, and statistical significance was assessed using the log-rank test. Univariate and multivariate analyses of Cox proportional hazards regression were used to evaluate the prognostic impact for survival in relapsed or refractory mCRC patients. Of the patients, 62.5% had liver metastases, 74.1% underwent greater than second-line chemotherapy, and 80.8% underwent surgery. Median OS was 7.6 months for all patients after the initiation of KM treatment, which was begun 13.7 months, on average, after mCRC diagnosis. Concerning prognostic factors such as the presence of liver metastasis (p = 0.024), high carcinoembryonic antigen level (CEA &gt; 5 ng/mL, p = 0.044), elevated C-reactive protein (CRP ≥ 10.0 mg/L, p = 0.000), high absolute monocyte count (AMC &gt; 413.3 cells/μL, p = 0.034), elevated serum ferritin (ferritin ≥ 150 ng/mL, p = 0.002), low hemoglobin level (Hb &lt; 12 g/dL, p = 0.026) and low albumin (albumin &lt; 3.5 g/dL, p = 0.003) were associated with increased hazard ratios and poor survival. According to the multivariate proportional hazards model with backward and forward manners, albumin (albumin &lt; 3.5 g/dL; hazard ratio (HR) 2.218, 95% confidence interval (CI) 1.135 - 3.990, p = 0.019), CRP (CRP ≥ 10.0 mg/L; HR 2.506, 95% CI 1.644 - 3.822, p = 0.000), CEA (CEA &gt; 5 ng/mL; HR 2.040, 95% CI 1.203 - 3.460, p = 0.008), and serum ferritin (ferritin ≥ 150 ng/mL; HR 1.763, 95% CI 1.169 - 2.660, p = 0.007) were independent prognostic biomarkers of survival in mCRC patients. These results indicate that serum ferritin acts as an independent prognostic biomarker for survival in relapsed or refractory mCRC patients.</description><subject>Research Paper</subject><issn>1837-9664</issn><issn>1837-9664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpVkU1vFDEMhiMEolXpoX8A5QiHLckmM85ckGDVAlJRqxbOkSfrKSmzk8XJrNR_T_pBVZyDo_jJm9ivEEdaHYNu1IebgMfaQgcvxL52BhZd29qXz_Z74jDnG1XDdEuw5rXYW4LRBly7L8Yr4nkjT4k5ljhJzBLlBafrKeUSg_wc0wb5N7EcEsurmXdxh6Os5CWNuM20lvX8kgbGUBLfyu9UMBe8u7tKY2IKpfIrnALxG_FqwDHT4WM-ED9PT36svi7Ozr98W306WwRrdVkAGlxDr9ahDaZTy8H1DQQFuoNmsNQgtogOutph19YFYEHZvncVX4YezYH4-KC7nfsNrQNNhXH0W461l1ufMPr_K1P85a_TzttOq8a5KvDuUYDTn5ly8ZuYA40jTpTm7HUdtwPlTFvR9w9o4JQz0_D0jFb-ziBfDfL3BlX27fN_PZH_7DB_AaR-jXI</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Lee, Sookyung</creator><creator>Song, Anna</creator><creator>Eo, Wankyu</creator><general>Ivyspring International Publisher</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160101</creationdate><title>Serum Ferritin as a Prognostic Biomarker for Survival in Relapsed or Refractory Metastatic Colorectal Cancer</title><author>Lee, Sookyung ; Song, Anna ; Eo, Wankyu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-7a3ad7b0dc6c3902f8b57c071975f4e5aa6aa87918396969774704bb86c32cba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Research Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Sookyung</creatorcontrib><creatorcontrib>Song, Anna</creatorcontrib><creatorcontrib>Eo, Wankyu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Sookyung</au><au>Song, Anna</au><au>Eo, Wankyu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum Ferritin as a Prognostic Biomarker for Survival in Relapsed or Refractory Metastatic Colorectal Cancer</atitle><jtitle>Journal of Cancer</jtitle><addtitle>J Cancer</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>7</volume><issue>8</issue><spage>957</spage><epage>964</epage><pages>957-964</pages><issn>1837-9664</issn><eissn>1837-9664</eissn><abstract>This study investigated the prognostic impact of serum ferritin for survival in patients with relapsed or refractory metastatic colorectal cancer (mCRC). This retrospective cohort study reviewed clinicopathological characteristics and laboratory biomarkers in 120 mCRC patients being treated with Korean Medicine (KM). The overall survival (OS) of patients was calculated using the Kaplan-Meier method, and statistical significance was assessed using the log-rank test. Univariate and multivariate analyses of Cox proportional hazards regression were used to evaluate the prognostic impact for survival in relapsed or refractory mCRC patients. Of the patients, 62.5% had liver metastases, 74.1% underwent greater than second-line chemotherapy, and 80.8% underwent surgery. Median OS was 7.6 months for all patients after the initiation of KM treatment, which was begun 13.7 months, on average, after mCRC diagnosis. Concerning prognostic factors such as the presence of liver metastasis (p = 0.024), high carcinoembryonic antigen level (CEA &gt; 5 ng/mL, p = 0.044), elevated C-reactive protein (CRP ≥ 10.0 mg/L, p = 0.000), high absolute monocyte count (AMC &gt; 413.3 cells/μL, p = 0.034), elevated serum ferritin (ferritin ≥ 150 ng/mL, p = 0.002), low hemoglobin level (Hb &lt; 12 g/dL, p = 0.026) and low albumin (albumin &lt; 3.5 g/dL, p = 0.003) were associated with increased hazard ratios and poor survival. According to the multivariate proportional hazards model with backward and forward manners, albumin (albumin &lt; 3.5 g/dL; hazard ratio (HR) 2.218, 95% confidence interval (CI) 1.135 - 3.990, p = 0.019), CRP (CRP ≥ 10.0 mg/L; HR 2.506, 95% CI 1.644 - 3.822, p = 0.000), CEA (CEA &gt; 5 ng/mL; HR 2.040, 95% CI 1.203 - 3.460, p = 0.008), and serum ferritin (ferritin ≥ 150 ng/mL; HR 1.763, 95% CI 1.169 - 2.660, p = 0.007) were independent prognostic biomarkers of survival in mCRC patients. These results indicate that serum ferritin acts as an independent prognostic biomarker for survival in relapsed or refractory mCRC patients.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher</pub><pmid>27313786</pmid><doi>10.7150/jca.14797</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1837-9664
ispartof Journal of Cancer, 2016-01, Vol.7 (8), p.957-964
issn 1837-9664
1837-9664
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4910588
source PubMed Central; EZB Electronic Journals Library; PubMed Central Open Access
subjects Research Paper
title Serum Ferritin as a Prognostic Biomarker for Survival in Relapsed or Refractory Metastatic Colorectal Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A55%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20Ferritin%20as%20a%20Prognostic%20Biomarker%20for%20Survival%20in%20Relapsed%20or%20Refractory%20Metastatic%20Colorectal%20Cancer&rft.jtitle=Journal%20of%20Cancer&rft.au=Lee,%20Sookyung&rft.date=2016-01-01&rft.volume=7&rft.issue=8&rft.spage=957&rft.epage=964&rft.pages=957-964&rft.issn=1837-9664&rft.eissn=1837-9664&rft_id=info:doi/10.7150/jca.14797&rft_dat=%3Cproquest_pubme%3E1797870836%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1797870836&rft_id=info:pmid/27313786&rfr_iscdi=true